GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » cbdMD Inc (AMEX:YCBD) » Definitions » EPS (Diluted)

cbdMD (YCBD) EPS (Diluted) : $-2.01 (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is cbdMD EPS (Diluted)?

cbdMD's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.22. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.01.

cbdMD's EPS (Basic) for the three months ended in Dec. 2024 was $-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.01.

cbdMD's EPS without NRI for the three months ended in Dec. 2024 was $-0.24. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.88.

During the past 3 years, the average EPS without NRIGrowth Rate was 53.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, cbdMD's highest 3-Year average EPS without NRI Growth Rate was 53.10% per year. The lowest was -9.80% per year. And the median was 6.95% per year.


cbdMD EPS (Diluted) Historical Data

The historical data trend for cbdMD's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

cbdMD EPS (Diluted) Chart

cbdMD Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.60 -21.15 -55.80 -13.32 -1.79

cbdMD Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -1.35 -0.15 -0.29 -0.22

Competitive Comparison of cbdMD's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


cbdMD's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, cbdMD's PE Ratio distribution charts can be found below:

* The bar in red indicates where cbdMD's PE Ratio falls into.



cbdMD EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

cbdMD's Diluted EPS for the fiscal year that ended in Sep. 2024 is calculated as

Diluted EPS (A: Sep. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.7-4.004)/4.313
=-1.79

cbdMD's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.015-1.001)/4.552
=-0.22

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


cbdMD  (AMEX:YCBD) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


cbdMD EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of cbdMD's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


cbdMD Business Description

Traded in Other Exchanges
Address
2101 Westinghouse Boulevard, Suite A, Charlotte, NC, USA, 28273
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Executives
Thomas Ronan Kennedy officer: Interim CEO and CFO 8845 RED OAK BLVD, CHARLOTTE NC 28217
Bakari T. Sellers director 4231 VOORHEES ROAD, DENMARK SC 29042
Raines William F Iii director 8314 TOSOMOCK LANE, HUNTERSVILLE NC 28078
Scott G. Stephen director 4249 NORTH WINCHESTER AVE., CHICAGO IL 60613
Sibyl Nichole Swift director 730 HAWTHORNE LANE, APT 441, CHARLOTTE NC 28204
Kevin Macdermott officer: President 9580 CALDWELL RD, MOUNT ULLA NC 28125
Wiesehan John J Iii officer: Chief Revenue Officer 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Sim Farar director 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Martin A. Sumichrast director, officer: Chairman of the Board and CEO 11125 COLONIAL COUNTRY LANE, CHARLOTTE NC 28277
Raymond Scott Coffman director 230 S. TRYON ST., #1302, CHARLOTTE NC 28202
Peter J. Ghiloni director 115 DEER ESTATES LANE, PONTE VEDRA BEACH FL 32082
Mark S Elliott officer: CFO & COO C/O LEVEL BRANDS, INC., 4521 SHARON ROAD, SUITE 450, CHARLOTTE NC 28211
Gregory C Morris director 421 CRANBORNE CHASE, FORT MILL SC 29708
Caryn Nicole Dunayer officer: President 8476 CATAWBA DOVE DR., BELMONT NC 28012
Erik Sterling 10 percent owner 5505 KALANIANAOLE HWY, HONOLULU HI 96821

cbdMD Headlines

From GuruFocus

Q3 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 08-16-2024

Q1 2025 cbdMD Inc Earnings Call Transcript

By GuruFocus News 02-14-2025

Q2 2021 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2020 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

cbdMD Inc Extraordinary Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q2 2023 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

cbdMD Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024